Company intelligence / Profile preview
Arctic Therapeutics
Reykjavik, Icelandarctictherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
Arctic Therapeutics is advancing two main programs. AT‑001 is an oral therapy targeting amyloid aggregation in the brain to treat hereditary cystatin C amyloid angiopathy and potentially other dementias including Alzheimer’s. It has received EMA approval to begin pivotal Phase IIb/III trials. Early research published in JAMA Neurology supports its mechanism. The second program, AT‑004, targets inflammatory skin diseases with a planned Phase IIa trial post-Series A financing. No commercial products yet.
- Therapeutic areas
- DermatologyRare DiseasesNeurology
- Modalities
- Small molecules (e.g., N-acetylcysteine for HCCAA)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Center for Applied Genomics at Children’s Hospital of PhiladelphiaSanos Group (strategic investor and board representation)
Beyond the preview
Go deeper on Arctic Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Arctic Therapeutics.